Clinical immunosuppression 2000

Transplant International

Volumn 13, Issue SUPPL. 1, 2000, Pages

  Soulillou, Jean Paul ^a   Giral, Magali ^a  

^a Institut de Transplantation et de Recherche en Transplantation Dieu   (France)

Author keywords

Clinical immunosuppression

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ANIMAL; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; REVIEW;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION IMMUNOLOGY;

EID: 18044375864     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2000.tb02019.x     Document Type: Article

References (11)

1. Giral-Classe M, Hourmant M, Cantarovich D, Dantal J, Blancho G, Daguin P, Ancelet D, Soulillou JP (1998) Delayed graft function of more than 6 days strongly decreases long-term survival of transplanted kidneys. Kidney Int 54: 972-978
2. Kahan BD (1997) Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 29: 36-41
3. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP (1997) Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350: 1193-1198
4. Hourmant M, Bedrossian J, Durand D, Lebranchu Y, Renoult E, Caudrelier P, Buffet R, Soulillou JP (1996) A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation 62: 1565-1570
5. Groth CG, Bakman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wrammer L, Brattstrom C, Charpentier B (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with ciclosporine. Sirolimus European Transplant Study Group. Transplantation 67: 1036-1042
6. Tkobashigawa JA, Katznelson S, Laks H, Jonhson JA, Yeatman L, Wang XM, Chia D, Terasaki P, Sabad A, Cogert GA, Traoslan K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinwater DC, Stevenson LW (1995) Effect of pravastatin on outcomes after cardiac transplantation 333: 621-627
7. Wenke R, Meiser B, Thiery J, Nagel D, Von Scheidt W, Steinbeck G, Seidel D, Reichart B (1997) Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four year randomized trial. Circulation 96: 1398-1402
8. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP (1998) Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence : randomised comparison of two cyclosporin regimens. Lancet 351: 623-628
9. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M (1999) Ciclosporine induces cancer progression by cell autonomous mechanism. Nature 397: 530-534
10. Kirk A, Burkly L, Batty D, Baumgartner R, Berning J, Buchanan K, Fechner J, Germond R, Kampen R, Patterson N, Swanson S, Tadaki D, Tendoor C, Whithe L, Knechtle S, Harlan D (1999) Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 5: 686-693
11. Zhong R, Zhang Z, Garcia B et al (1998) Prevention of rejection and induction of tolerance by monoclonal antibody to CD45RB in monkey kidney transplant model - a preliminary report (abstract no. 25). ASTS 24th meeting